Author: Qi Liu; Amita Gupta; Ayse Okesli-Armlovich; Wenjie Qiao; Curt R. Fischer; Mark Smith; Jan E. Carette; Michael C. Bassik; Chaitan Khosla
Title: Enhancing the Antiviral Efficacy of RNA-Dependent RNA Polymerase Inhibition by Combination with Modulators of Pyrimidine Metabolism Document date: 2020_3_25
ID: 1zk64gsg_103
Snippet: . CC-BY-NC 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.24.992230 doi: bioRxiv preprint For tests of the CPU-GSK983 combination ( Figure 5B) ,For the accompanying cell viability assay, A549 cells were seeded into 24-well plates at a density of 20,000 cells/well incubated for 24 h at 37 °C. Cell were then treated .....
Document: . CC-BY-NC 4.0 International license author/funder. It is made available under a The copyright holder for this preprint (which was not peer-reviewed) is the . https://doi.org/10.1101/2020.03.24.992230 doi: bioRxiv preprint For tests of the CPU-GSK983 combination ( Figure 5B) ,For the accompanying cell viability assay, A549 cells were seeded into 24-well plates at a density of 20,000 cells/well incubated for 24 h at 37 °C. Cell were then treated with pyrimidine de novo synthesis and/or salvage inhibitors in DMEM supplemented with 20 µM uridine. Following 48h treatment, cells were harvested, and the density of viable cells was determined by flow cytometry (FSC/SSC) using a BD Accuri C6 Flow Cytometer.
Search related documents:
Co phrase search for related documents- cell density and viable cell: 1
- cell density and viable cell density: 1
- cell viability and de novo synthesis: 1, 2, 3
- cell viability and flow cytometry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55
- cell viability and novo synthesis: 1, 2, 3
- cell viability and pyrimidine de novo synthesis: 1
- cell viability and viable cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- cell viability and viable cell density: 1
- cell viability assay and de novo synthesis: 1, 2
- cell viability assay and flow cytometry: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- cell viability assay and novo synthesis: 1, 2
- cell viability assay and pyrimidine de novo synthesis: 1
- cell viability assay and viable cell: 1, 2
- de novo synthesis and flow cytometry: 1
- de novo synthesis and novo synthesis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- de novo synthesis and pyrimidine de novo synthesis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- flow cytometry and FSC SSC flow cytometry: 1
- flow cytometry and novo synthesis: 1
- flow cytometry and viable cell: 1, 2, 3, 4, 5, 6, 7
Co phrase search for related documents, hyperlinks ordered by date